Lung Cancer Vaccine Being Tested at Rhode Island & Miriam Hospitals
Tuesday, December 07, 2010
Local Participants Sought
Led locally by the thoracic oncology team at Rhode Island Hospital and The Miriam Hospital, including thoracic surgeon Thomas Ng, MD; radiation oncologist Thomas Dipetrillo, MD; and medical oncologists Angela Plette, MD and Humera Khurshid, MD, the study will examine a new vaccine that triggers the body’s immune system to activate a response against cancer cells. Participants will either receive a series of 13 doses of the vaccine or a placebo, and participate in follow-up visits to be scheduled every two months for the remainder of the first year, and every three months for the next two years.
Patients who may be eligible to participate in the study must meet the following criteria:
• 18 years of age or older
• have been diagnosed with Stage IB- IIIA non-small cell lung cancer
• have undergone surgical resection of the lung cancer and show no evidence of disease following surgery
• Additional criteria must also be met and eligibility for participation will be determined by the research team.
The trial is sponsored by GlaxoSmithKline. For more information, please call the Lifespan Oncology Clinical Research Office at Rhode Island Hospital at 444-8856 or The Miriam Hospital at 793-4283 or visit www.lifespan.org/services/clintrials/ccc/trials/lung.htm
Related Articles
- Brown Study Will Test Fruit and Vegetable Consumption Incentives in the Workplace
- Miriam Hospital Study: Olive Oil Diet Benefits Prostate Cancer Survivors
- New Study at Miriam Hospital Targets Weight Gain Prevention in Young Adults
- New Study: Quitting Smoking Also Makes You Happier
Follow us on Pinterest Google + Facebook Twitter See It Read It